Recombinant exenatide-4 - CSPC

Drug Profile

Recombinant exenatide-4 - CSPC

Alternative Names: rE4; rExenatide-4 - CSPC

Latest Information Update: 03 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSPC Pharma
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 08 Aug 2017 CSPC ZhongQi Pharmaceutical plans a phase III trial for Type-2 diabetes mellitus (Treatment-experienced) (NCT03239119)
  • 21 Jan 2017 CSPC ZhongQi Pharmaceutical Technology completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in China (NCT03199261)
  • 23 Dec 2016 CSPC ZhongQi Pharmaceutical Technology initiates enrolment in a phase I trial for Type-2 diabetes mellitus (In volunteers) in China (NCT03199261)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top